A to Z Summary Results - Patient Decision Aids - Ottawa Hospital Research Institute 


Decision Aid Summary

Title Whether or not to take levodopa-carbidopa intestinal gel (LCIG) to control the symptoms of Parkinson’s disease (PD). --- Prendre ou non le gel intestinal de levodopa/carbidopa (GILC) pour maîtriser les symptômes de la maladie de Parkinson (MP).
To access it Click here to view the decision aid on the developer website
Audience Patients with advance Parkinson Disease and their caregivers (if applicable).
Options included TO TAKE levodopa/carbidopa intestinal gel (LCIG).
NOT TO TAKE levodopa/carbidopa intestinal gel (LCIG).
Year of last update or review 2022
Format Web, paper, PDF
Developer Caroline Cayer
Where was it developed? caroline.cayer.ciussse-chus@ssss.gouv.qc.ca
CIUSSS de l'Estrie-CHUS
Canada
Health condition Parkinson's Disease
Type of decision aid Treatment
Language French
Based on IPDAS criteria (International Patient Decision Aid Standards) this decision aid (and/or supporting materials) meets:
7 out of 7 criteria to be defined as a patient decision aid
8 out of 8 criteria to lower the risk of making a biased decision
Not applicable: other criteria for decision aids about screening or testing

Last modified: 2024-03-04.